Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 62 of the 65 references it cites were found in a registry or an index; 14 of the 63 sources its claims cite were checked for support.

Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis

Open access

Abstract

Background Timely, accurate, and comprehensive estimates of SARS-CoV-2 daily infection rates, cumulative infections, the proportion of the population that has been infected at least once, and the effective reproductive number (R effective ) are essential for understanding the determinants of past infection, current transmission patterns, and a population's susceptibility to future infection with the same variant. Although several studies have estimated cumulative SARS-CoV-2 infections in select locations at specific points in time, all of these analyses have relied on biased data inputs that were not adequately corrected for. In this study, we aimed to provide a novel approach to estimating past SARS-CoV-2 daily infections, cumulative infections, and the proportion of the population infected, for 190 countries and territories from the start of the pandemic to Nov 14, 2021. This approach combines data from reported cases, reported deaths, excess deaths attributable to COVID-19, hospitalisations, and seroprevalence surveys to produce more robust estimates that minimise constituent biases. Methods We produced a comprehensive set of global and location-specific estimates of daily and cumulative SARS-CoV-2 infections through Nov 14, 2021, using data largely from Johns Hopkins University (Baltimore, MD, USA) and national databases for reported cases, hospital admissions, and reported deaths, as well as seroprevalence surveys identified through previous reviews, SeroTracker, and governmental organisations. We corrected these data for known biases such as lags in reporting, accounted for under-reporting of deaths by use of a statistical model of the proportion of excess mortality attributable to SARS-CoV-2, and adjusted seroprevalence surveys for waning antibody sensitivity, vaccinations, and reinfection from SARS-CoV-2 escape variants. We then created an empirical database of infection–detection ratios (IDRs), infection–hospitalisation ratios (IHRs), and infection–fatality ratios (IFRs). To estimate a complete time series for each location, we developed statistical models to predict the IDR, IHR, and IFR by location and day, testing a set of predictors justified through published systematic reviews. Next, we combined three series of estimates of daily infections (cases divided by IDR, hospitalisations divided by IHR, and deaths divided by IFR), into a more robust estimate of daily infections. We then used daily infections to estimate cumulative infections and the cumulative proportion of the population with one or more infections, and we then calculated posterior estimates of cumulative IDR, IHR, and IFR using cumulative infections and the corrected data on reported cases, hospitalisations, and deaths. Finally, we converted daily infections into a historical time series of R effective by location and day based on assumptions of duration from infection to infectiousness and time an individual spent being infectious. For each of these quantities, we estimated a distribution based on an ensemble framework that captured uncertainty in data sources, model design, and parameter assumptions. Findings Global daily SARS-CoV-2 infections fluctuated between 3 million and 17 million new infections per day between April, 2020, and October, 2021, peaking in mid-April, 2021, primarily as a result of surges in India. Between the start of the pandemic and Nov 14, 2021, there were an estimated 3·80 billion (95% uncertainty interval 3·44–4·08) total SARS-CoV-2 infections and reinfections combined, and an estimated 3·39 billion (3·08–3·63) individuals, or 43·9% (39·9–46·9) of the global population, had been infected one or more times. 1·34 billion (1·20–1·49) of these infections occurred in south Asia, the highest among the seven super-regions, although the sub-Saharan Africa super-region had the highest infection rate (79·3 per 100 population [69·0–86·4]). The high-income super-region had the fewest infections (239 million [226–252]), and southeast Asia, east Asia, and Oceania had the lowest infection rate (13·0 per 100 population [8·4–17·7]). The cumulative proportion of the population ever infected varied greatly between countries and territories, with rates higher than 70% in 40 countries and lower than 20% in 39 countries. There was no discernible relationship between R effective and total immunity, and even at total immunity levels of 80%, we observed no indication of an abrupt drop in R effective , indicating that there is not a clear herd immunity threshold observed in the data. Interpretation COVID-19 has already had a staggering impact on the world up to the beginning of the omicron (B.1.1.529) wave, with over 40% of the global population infected at least once by Nov 14, 2021. The vast differences in cumulative proportion of the population infected across locations could help policy makers identify the transmission-prevention strategies that have been most effective, as well as the populations at greatest risk for future i

Overview

CoChat Summary

TL;DR

Barber et al. estimated global, regional, and national daily and cumulative SARS-CoV-2 infections through Nov 14, 2021 by triangulating reported cases, hospitalisations, deaths, excess mortality, and seroprevalence data. They estimated 3.80 billion infections/reinfections and 3.39 billion individuals infected at least once, or 43.9% of the global population, with no clear herd immunity threshold observed.

Key findings

  • Global daily infections fluctuated between 3 million and 17 million new infections per day from April, 2020, to October, 2021, peaking in mid-April, 2021, primarily due to surges in India.
  • By Nov 14, 2021, there were an estimated 3.80 billion (95% UI 3.44–4.08) total SARS-CoV-2 infections and reinfections combined, and 3.39 billion (3.08–3.63) individuals, or 43.9% (39.9–46.9) of the global population, had been infected one or more times.
  • South Asia had the most infections (1.34 billion [1.20–1.49]); sub-Saharan Africa had the highest infection rate (79.3 per 100 population [69.0–86.4]); the high-income super-region had the fewest infections (239 million [226–252]); southeast Asia, east Asia, and Oceania had the lowest infection rate (13.0 per 100 [8.4–17.7]). Over 70% of the population had been infected in 40 countries and under 20% in 39 countries.
  • There was no discernible relationship between Reffective and total immunity, and even at total immunity levels of 80%, no abrupt drop in Reffective was observed, indicating no clear herd immunity threshold in the data.

Methods

  • The study used a seven-step ensemble framework: corrected reported cases, hospitalisations, and deaths for reporting lags and under-reporting; adjusted 2817 seroprevalence survey datapoints for vaccination, waning antibody sensitivity, and reinfection from escape variants; and created empirical databases of infection–detection ratios (IDRs), infection–hospitalisation ratios (IHRs), and infection–fatality ratios (IFRs).
  • Bayesian cascading regression models predicted IDR, IHR, and IFR by location and day using covariates including testing, universal health-care coverage, HAQ Index, age structure, and comorbidities; three daily infection series (cases/IDR, hospitalisations/IHR, deaths/IFR) were combined into a robust daily infection estimate, then summed to cumulative infections and the cumulative proportion infected at least once, and converted to Reffective.
  • Estimates covered 190 countries and territories, subnational locations in ten countries, 21 regions, seven super-regions, and globally through Nov 14, 2021, with a 100-iteration ensemble to capture uncertainty in data sources, model design, and parameter assumptions.

Limitations

  • The paper states that some seroprevalence surveys may be biased and corrections were inconsistent; the testing-capacity covariate cannot decline, so declines in effective testing may be missed; vaccination adjustments sometimes produced decreasing seroprevalence estimates, leading to exclusion of those data; interval IDR/IHR/IFR measures limit identification of short-term fluctuations; hospital admissions data were sparse in low- and middle-income settings; total COVID-19 mortality estimates had wide uncertainty intervals; and the model allowed a maximum of two infections per individual.
  • The paper also notes that its analysis ends before the omicron wave and that omicron’s transmissibility and immune escape mean the findings should not be extrapolated to later periods.
  • Evident from the text: the estimates depend on many modelling assumptions and covariates, and the lack of a clear herd immunity threshold may reflect confounding by seasonality, physical distancing, mask use, and new variant spread rather than immunity alone.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(22)00484-6

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Empirical measurements over time of infection–detection ratios (A), age-standardised infection–hospitalisation ratios (B), and age-standardised infection–fatality ratios (C) The y-axis for infection–hospitalisation ratios and infection–fatality ratios is shown in log base 10.
Figure 1 Empirical measurements over time of infection–detection ratios (A), age-standardised infection–hospitalisation ratios (B), and age-standardised infection–fatality ratios (C) The y-axis for infection–hospitalisation ratios and infection–fatality ratios is shown in log base 10.CC BY · PubMed Central
Figure 2 Daily (A) and cumulative (B) infections by super-region from Feb 4, 2020, to Nov 14, 2021
Figure 2 Daily (A) and cumulative (B) infections by super-region from Feb 4, 2020, to Nov 14, 2021CC BY · PubMed Central
Figure 3 Cumulative proportion of the population infected with SARS-CoV-2 at least once by Nov 14, 2021, by country and territory The first administrative level is mapped for countries that are modelled at that level and have a population greater than 100 million.
Figure 3 Cumulative proportion of the population infected with SARS-CoV-2 at least once by Nov 14, 2021, by country and territory The first administrative level is mapped for countries that are modelled at that level and have a population greater than 100 million.CC BY · PubMed Central
Figure 4 Reffective by total immunity Proportion of total immunity shown starting at 1%. Reffective=effective reproductive number.
Figure 4 Reffective by total immunity Proportion of total immunity shown starting at 1%. Reffective=effective reproductive number.CC BY · PubMed Central

Verification

Claims the paper makes

7 Valid · 6 Not valid · 25 Not checked · 127 Own results and interpretations

97 more claims · 2 with their cited sources checked

Create a free account to see all 165 claims and to verify the 42 references still open.

See all claims — free account
  • Probably not a substantial claim. 36
  • It may state two separate claims as one. 36

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 65 references

Cited by

See all 302

Metadata

Authors
Barber, R. M., Sorensen, R. J. D., Pigott, D. M., Bisignano, C., Carter, A., Amlag, J. O., Collins, J. K., Abbafati, C., Adolph, C., Allorant, A., Aravkin, A. Y., Bang-Jensen, B. L., Castro, E., Chakrabarti, S., Cogen, R. M., Combs, E., Comfort, H., Cooperrider, K., Dai, X., Daoud, F., Deen, A., Earl, L., Erickson, M., Ewald, S. B., Ferrari, A. J., Flaxman, A. D., Frostad, J. J., Fullman, N., Giles, J. R., Guo, G., He, J., Helak, M., Hulland, E. N., Huntley, B. M., Lazzar-Atwood, A., LeGrand, K. E., Lim, S. S., Lindstrom, A., Linebarger, E., Lozano, R., Magistro, B., Malta, D. C., Månsson, J., Mantilla Herrera, A. M., Mokdad, A. H., Monasta, L., Naghavi, M., Nomura, S., Odell, C. M., Olana, L. T., Ostroff, S. M., Pasovic, M., Pease, S. A., Reiner Jr, R. C., Reinke, G., Ribeiro, A. L. P., Santomauro, D. F., Sholokhov, A., Spurlock, E. E., Syailendrawati, R., Topor-Madry, R., Vo, A. T., Vos, T., Walcott, R., Walker, A., Wiens, K. E., Wiysonge, C. S., Worku, N. A., Zheng, P., Hay, S. I., Gakidou, E., & Murray, C. J. L.
Corresponding author
Barber, Ryan M
Venue
The Lancet
Publisher
Elsevier BV
Published
2022-06
Volume
399
Issue
10344
Pages
2351-2380
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W4223443877
Cited by
298
References
65
Citations by year
2026: 21 · 2025: 26 · 2024: 80 · 2023: 105 · 2022: 66
FWCI
41.46
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • ePrints Soton (University of Southampton) (acceptedVersion)
  • LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, other-oa)
Funders
  • Queensland Government
  • Queensland Health
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico (310679/2016-8, 465518/2014-1)
  • National Health and Medical Research Council (APP1121516)
  • Fundação de Amparo à Pesquisa do Estado de Minas Gerais (PPM-00428-17, RED-00081-16)
  • South African Medical Research Council
  • National Science Foundation (2031096)
  • Ministry of Education, Culture, Sports, Science and Technology
  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (88887.507149/2020-00)
  • New York State Department of Health
  • Bill and Melinda Gates Foundation
Topics
  • Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Health Sciences › Medicine › Epidemiology › Data-Driven Disease Surveillance
Keywords
SARS-CoV-2, COVID-19 pandemic, cumulative infections, infection fatality rate, excess mortality, seroprevalence, effective reproduction number, reinfection, escape variants, vaccination, global estimates, country-level estimates, time series forecasting, SARS-CoV-2 variants
MeSH terms
COVID-19, SARS-CoV-2, Humans, Seroepidemiologic Studies, Pandemics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis. https://app.cochat.ai/papers/10.1016/s0140-6736(22)00484-6
The paper
Barber, R. M., Sorensen, R. J. D., Pigott, D. M., Bisignano, C., Carter, A., Amlag, J. O., Collins, J. K., Abbafati, C., Adolph, C., Allorant, A., Aravkin, A. Y., Bang-Jensen, B. L., Castro, E., Chakrabarti, S., Cogen, R. M., Combs, E., Comfort, H., Cooperrider, K., Dai, X., . . . Murray, C. J. L. (2022). Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis. The Lancet. https://doi.org/10.1016/s0140-6736(22)00484-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.